Canaccord analyst Kyle Mikson lowered the firm’s price target on Castle Biosciences (CSTL) to $40 from $50 and keeps a Buy rating on the shares. The firm updated its model and believes the company remains a focus stocks, and they believe the company has solid operating momentum and multiple catalysts that could support long-term revenue growth.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences to present new data from DecisionDx-Melanoma test at AAD
- Castle announces publication of DecisionDx-Melanoma’s i31-SLNB study results
- Castle Biosciences announces new data from study evaluating i31SLNB
- Castle Biosciences Balances Strong Growth With Margin Strain
- Castle Biosciences: Strong Assay Momentum and Underpenetrated Market Support Buy Rating and $50 Price Target